Literature DB >> 17531174

Antiphospholipid antibodies in response to infection.

Tadej Avcin1, Natasa Toplak.   

Abstract

An association between infections and antiphospholipid antibodies (aPL) has been reported in several epidemiologic and experimental studies. Infection-induced aPL have been traditionally regarded as transient and were generally not associated with clinical features of antiphospholipid syndrome. The distinction between autoimmune and postinfectious aPL on the basis of requirement of binding cofactor is not absolute, and in recent years, several reports demonstrated that some patients can produce pathogenic antibodies in response to infection. Infections most frequently associated with antiphospholipid syndrome include parvovirus B19, cytomegalovirus, varicella-zoster virus, HIV, streptococcal and staphylococcal infections, gram-negative bacteria, and Mycoplasma pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531174     DOI: 10.1007/s11926-007-0034-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  55 in total

1.  Henoch-Schonlein purpura with antiphospholipid antibodies after influenza vaccination: how fearful is it in children?

Authors:  Raffaella Mormile; Vincenzo D'Alterio; Gennaro Treccagnoli; Pasquale Sorrentino
Journal:  Vaccine       Date:  2004-12-16       Impact factor: 3.641

Review 2.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

3.  Influenza vaccination and the production of anti-phospholipid antibodies in patients with systemic lupus erythematosus.

Authors:  P Tarján; S Sipka; G Lakos; E Kiss; G Ujj; G Szegedi
Journal:  Scand J Rheumatol       Date:  2006 May-Jun       Impact factor: 3.641

4.  Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection.

Authors:  Katrin Frauenknecht; Karl Lackner; Philipp von Landenberg
Journal:  Immunobiology       Date:  2005-10-21       Impact factor: 3.144

5.  Antibodies to beta 2-glycoprotein I and cardiolipin with symptoms suggestive of systemic lupus erythematosus in parvovirus B19 infection.

Authors:  M Kalt; E Gertner
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

6.  Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo.

Authors:  Azzudin E Gharavi; Silvia S Pierangeli; Ricardo G Espinola; Xiaowei Liu; Margaret Colden-Stanfield; E Nigel Harris
Journal:  Arthritis Rheum       Date:  2002-02

7.  Anticardiolipin response in acute infections.

Authors:  O Vaarala; T Palosuo; M Kleemola; K Aho
Journal:  Clin Immunol Immunopathol       Date:  1986-10

8.  Anticardiolipin antibodies in acute poststreptococcal glomerulonephritis and streptococcal impetigo.

Authors:  L Ardiles; P Ramirez; P Moya; I Caorsi; S Mezzano
Journal:  Nephron       Date:  1999-09       Impact factor: 2.847

9.  Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.

Authors:  Philipp Von Landenberg; Hartwig W Lehmann; Antje Knöll; Simone Dorsch; Susanne Modrow
Journal:  Arthritis Rheum       Date:  2003-07

10.  Mycoplasma pneumonia with antiphospholipid antibodies and a cardiac thrombus.

Authors:  M Bakshi; C Khemani; V Vishwanathan; R K Anand; R P Khubchandani
Journal:  Lupus       Date:  2006       Impact factor: 2.911

View more
  20 in total

Review 1.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

3.  Altered frequency and phenotype of CD4+ forkhead box protein 3+ T cells and its association with autoantibody production in human immunodeficiency virus-infected paediatric patients.

Authors:  R J Argüello; J Balbaryski; G Barboni; M Candi; E Gaddi; S Laucella
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

4.  Clinical and laboratory characteristics of children positive for antiphospholipid antibodies.

Authors:  Paola Giordano; Riccardina Tesse; Giuseppe Lassandro; Deborah Fracchiolla; Prudenza Ranieri; Antonella Lotito; Domenico De Mattia; Giovanni Carlo Del Vecchio
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

Review 5.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

Review 6.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

7.  Acute postoperative inflammatory polyarthritis associated with a lone IgM cardiolipin antibody.

Authors:  Ignatius Chua; Ali Jawad
Journal:  BMJ Case Rep       Date:  2015-03-02

8.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

Review 9.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.

Authors:  Cassyanne L Aguiar; Doruk Erkan
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

Review 10.  Perioperative management of antiphospholipid antibody-positive patients.

Authors:  Katherine H Saunders; Doruk Erkan; Michael D Lockshin
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.